Pharma Focus Europe

ARTBIO and Nucleus RadioPharma Team Up to Produce GMP-Grade Therapeutic Products Featuring Radioisotope Pb-212 in Support of Emerging Clinical Trials

Wednesday, May 08, 2024

ARTBIO, Inc. (ARTBIO), a company focused on clinical-stage radiopharmaceutical development specializing in targeted alpha radioligand therapies (ARTs), has partnered with Nucleus RadioPharma Inc. (Nucleus), a leader in integrated development, manufacturing, and supply chain management for radiopharmaceuticals. Together, they've formed a strategic manufacturing and supply agreement to enhance ARTBIO’s therapeutic product manufacturing.

Nucleus will manufacture ARTBIO’s 212Pb-radiolabeled therapies for the upcoming Phase I and II clinical trials of its lead program, AB001, targeting prostate cancer. They will utilize ARTBIO’s proprietary AlphaDirectTM 212Pb isolation technology at their facility in Rochester, Minn., serving patients in the Northern and Midwest regions of the United States.

ARTBIO, stressed the importance of selecting partners who share their patient-centric approach, stating, “As we continue building our distributed manufacturing capabilities in the U.S. and globally, selecting partners who share our patient-centric vision is critical.” He expressed confidence in Nucleus’s commitment to making targeted radiopharmaceutical therapies accessible, aiming to introduce a new class of alpha radioligand therapies to hospitals across Minnesota and beyond.

Nucleus, echoed this sentiment, emphasizing their shared mission to revolutionize cancer treatment through innovative therapies. He commented, “This strategic partnership with ARTBIO underscores our unwavering commitment to transforming the lives of cancer patients through groundbreaking therapies.” Conroy highlighted their excitement to collaborate in addressing the growing demand for innovative radiopharmaceuticals, ensuring patients have access to potentially life-changing treatments while upholding the highest standards of quality and supply chain resilience.

At the heart of this collaboration is AlphaDirectTM, a system designed by ARTBIO, delivering highly pure 212Pb sourced from readily available raw materials. Recognized for its alpha-emitting properties and attractive short half-life, 212Pb holds significant promise for therapeutic applications, particularly in targeted alpha radioligand therapy. Early studies on radiopharmaceuticals labeled with 212Pb have shown promising results, suggesting its potential to meet unmet clinical needs effectively.

 

Source: businesswire.com

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva